Lineage Cell Therapeutics (LCTX) Interest Expenses (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Interest Expenses of $11.7 million for Q1 2026, up 3747.87% year-over-year from $305000.0 in Q1 2025, and up 3698.06% quarter-over-quarter from $309000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Interest Expenses (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Interest Expenses history runs 16 years deep, the most recent figure standing at $11.7 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 3747.87% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $11.7 million (up 3851.52% YoY), while the FY2025 annual figure was $89.4 million, up 3.6% from the prior year.
- Interest Expenses for Q1 2026 stood at $11.7 million, up from $309000.0 in the prior quarter.
- The five-year high for Interest Expenses was $15.1 million in Q3 2025, with the low at -$633000.0 in Q4 2023.
- The 5-year median for Interest Expenses is $453000.0 (2023), against an average of $2.1 million.
- The sharpest annual moves came in 2023 and 2026: Interest Expenses tumbled 297.81% in 2023, then jumped 3747.87% in 2026.
- Lineage Cell Therapeutics' Interest Expenses stood at $320000.0 in 2022, then sank by 297.81% to -$633000.0 in 2023, then jumped by 148.18% to $305000.0 in 2024, then increased by 1.31% to $309000.0 in 2025, then surged by 3698.06% to $11.7 million in 2026.
- Business Quant data shows LCTX's Interest Expenses at $11.7 million in Q1 2026, $309000.0 in Q4 2025, and $15.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 6.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.69 Mn |
| Jun 30, 2026 | 6.69 Mn |
| Mar 31, 2026 | 11.74 Mn |
| Mar 31, 2026 | 11.74 Mn |
| Dec 31, 2025 | 309,000.00 |
| Dec 31, 2025 | 309,000.00 |
| Sep 30, 2025 | 15.06 Mn |
| Sep 30, 2025 | 15.06 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Mar 31, 2025 | 305,000.00 |
| Mar 31, 2025 | 305,000.00 |
| Dec 31, 2024 | 305,000.00 |
| Dec 31, 2024 | 305,000.00 |
| Sep 30, 2024 | 730,000.00 |
| Sep 30, 2024 | 730,000.00 |
| Jun 30, 2024 | 724,000.00 |
| Jun 30, 2024 | 724,000.00 |
| Mar 31, 2024 | 2.49 Mn |
| Mar 31, 2024 | 2.49 Mn |